53rd week of 2015 patent applcation highlights part 10 |
Patent application number | Title | Published |
20150374800 | Inhibitors of Branched-Chain-Aminotransferase-1 (BCAT1) for the Treatment of Brain Tumors - Described is a compound capable of reducing or inhibiting (a) the biological activity of branched-chain-aminotrans-ferase-1 (BCATI) or (b) the expression of the gene encoding BCATI for use in a method of treating a neoplasia. A preferred compound is 1-(aminomethyl)cyclohexaneacetic acid (gabapentin). | 2015-12-31 |
20150374801 | PROTEINS WITH MODIFIED GLYCOSYLATION AND METHODS OF PRODUCTION THEREOF - In one aspect, the disclosure provides proteins with modified glycosylation and methods of their production. In aspect, the disclosure provides transgenic animals and cells for the production of proteins with modified glycosylation. In some embodiment, the modified glycosylation is increased sialylation. | 2015-12-31 |
20150374802 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISEASES - The invention provides compositions and methods for treating inflammatory diseases, such as cardiac or hepatic inflammatory diseases, involving the use of parasite-derived neurotrophic factor (PDNF), or fragment of PDNF. The invention also provides compositions featuring PDNF, or a fragment thereof, and methods for using such compositions for the proliferation and/or mobilization of a stem cell (e.g., cardiac stem cell) or progenitor cell (e.g., hepatic progenitor cell). In one aspect, the invention provides a method of decreasing inflammation in a nonneuronal tissue of a subject. In another aspect, the invention provides a method of decreasing inflammation in a cardiac, liver, pancreas, or gastrointestinal tissue of a subject. In still another aspect, the invention provides a method of increasing expression of an anti-inflammatory factor in a non-neuronal cell or tissue | 2015-12-31 |
20150374803 | ADENO-ASSOCIATED VIRUS VECTORS AND METHODS OF USE THEREOF - The present invention provides AAV vectors and methods of use thereof for delivery of transgenes or therapeutic nucleic acids to subjects. | 2015-12-31 |
20150374804 | TREATMENT OF DISEASES RELATED TO HYPERACTIVITY OF THE COMPLEMENT SYSTEM - Raising the level of Factor I above physiological levels can be used to treat diseases in which the underlying pathology is linked to overactivity of the C3b-feedback cycle and the generation and pro-inflammatory effects of iC3b. Methods, agents, and compositions for treatment of such diseases are described. | 2015-12-31 |
20150374805 | USE OF BOTULINUM TOXIN THERAPY FOR TREATMENT OF UROLOGICAL NEUROLOGICAL CONDITIONS - The present invention relates to methods for treating neurological-urological conditions. This is accomplished by administration of at least one neurotoxin. | 2015-12-31 |
20150374806 | LOCAL ENGINEERING OF THE LYMPH NODE ENVIRONMENT TO PROMOTE IMMUNE TOLERANCE - A method of inducing specific immune tolerance to myelin in an individual is provided. The method includes introducing directly into a lymph node of the individual an effective amount of a composition that contains a myelin antigen, a biodegradable material and at least one tolerogenic agent. The method is suitable for reducing the severity of symptoms of multiple sclerosis in individuals who suffer from primary-progressive multiple sclerosis (PPMS), and can halt or even reverse PPMS progression. | 2015-12-31 |
20150374807 | Amyloid beta1-6 Antigen Arrays - The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array, and in particular an Aβ1-peptide-VLP-composition. More specifically, the invention provides a composition comprising a virus-like particle and at least one Aβ1-6 peptide bound thereto. The invention also provides a process for producing the conjugates and the ordered and repetitive arrays, respectively. The compositions of the invention are useful in the production of vaccines for the treatment of Alzheimer's disease and as a pharmaccine to prevent or cure Alzheimer's disease and to efficiently induce immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune, responses within the indicated context. | 2015-12-31 |
20150374808 | Her2 DNA Vaccine as Adjunct Treatment for Cancers in Companion Animals - The application discloses therapeutic vaccines based upon the “pING” DNA plasmid vector expressing the gene encoding the rat Her2 protein. Vaccines according to the instant disclosure are used as an adjunct treatment for surgery, radiation and/or chemotherapy for dogs and cats with cancers that over express the Her2 antigen, and prolong the post-surgical disease free interval and/or survival time. Also included are therapeutically effective methods of immunization using said vaccines. | 2015-12-31 |
20150374809 | TUMOR VACCINES AND METHODS OF USE THEREOF - The present invention provides a therapeutic agent comprising an antibody-recognition epitope (ARE) covalently bound to a tumor cell, wherein the ARE is bound to an antibody that is specific for the ARE, to form a tumor cell:ARE:antibody complex, and kits and methods of using these tumor cell:ARE:antibody complexes. | 2015-12-31 |
20150374810 | TOMM34 PEPTIDES AND VACCINES INCLUDING THE SAME - The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 42, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include one of the above mentioned amino acid sequences with substitution, deletion, or addition of one, two, or several amino acids sequences. The present invention also provides pharmaceutical compositions including these peptides. The peptides of this invention can be used for treating cancer. | 2015-12-31 |
20150374811 | PROTEIN ANTIGENS THAT PROVIDE PROTECTION AGAINST PNEUMOCOCCAL COLONIZATION AND/OR DISEASE - The present application is generally directed to novel pneumococcal polypeptide antigens and nucleic acids encoding such antigens, and immunogenic compositions comprising such antigens for treating and preventing pneumococcal infection. The present invention further provides method of using the antigens to elicits an immune response (e.g., IL-17A response, a T cell-mediated and/or B-cell-mediated immune responses). The present invention also provides methods of prophylaxis and/or treatment of pneumococcal-mediated diseases, such as sepsis, comprising administering an immunogenic composition including one or more of a combination of pneumococcal antigens or functional fragments thereof as disclosed herein. In some embodiments, one or more pneumococcal antigens can be present in a polysaccharide conjugate. The compositions induce an anti-pneumoccocus immune response when administered to a mammal. The compositions can be used prophylactically to vaccinate an individual and/or therapeutically to induce a thereapeutic immune response to an infected individual. | 2015-12-31 |
20150374812 | CELL LINES FOR VIRUS PRODUCTION AND METHODS OF USE - Provided herein are engineered cell lines. In some embodiments, cells of an engineered cell line have altered expression of a gene and/or altered expression of an miRNA, wherein the altered expression results in increased or decreased production of a virus. The virus is a picomavirus, such as a poliovirus or Enterovirus 71. Also provided herein are methods for using the engineered cells to produce virus, and methods for treating a subject having or at risk of having a viral infection. | 2015-12-31 |
20150374813 | FUNCTIONAL INFLUENZA VIRUS LIKE PARTICLES (VLPs) - The present invention discloses and claims virus like particles (VLPs) that express and/or contains seasonal influenza virus proteins, avian influenza virus proteins and/or influenza virus proteins from viruses with pandemic potential. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising VLPs of the inventions. The invention also includes methods of making and administrating VLPs to vertebrates, including methods of inducing substantial immunity to either seasonal and avian influenza, or at least one symptom thereof. | 2015-12-31 |
20150374814 | Polyvalent Fusion Protein Vaccine Against Influenza - The problem to be solved: absence of safe efficient universal vaccine against influenza. The solution: The vaccine based on the fusion protein consisting of antigenic determinants of haemagglutinins of influenza A and B viruses and flagellin fragments functioning as safe adjuvant (SEQ ID NO:1) joined via flexible hinges is given which can be used for prophylaxis of influenza caused by existing influenza A and B strains as well as by possible reassortants. Safety, efficacy, polyvalence and preventive effect have been demonstrated. Usage of the present vaccine will allow to provide a universal protection against influenza. | 2015-12-31 |
20150374815 | METHODS AND COMPOSITIONS FOR TREATMENT WITH SYNTHETIC NANOCARRIERS AND IMMUNE CHECKPOINT INHIBITORS - Disclosed are synthetic nanocarrier compositions and immune checkpoint inhibitor compositions and related methods for administration to a subject. | 2015-12-31 |
20150374816 | DESIGN OF SHORT OLIGONUCLEOTIDES AS VACCINE ADJUVANTS AND THERAPEUTIC AGENTS - The invention provides a method of treating a microbial infection in a subject and a method of improving an immune system response in a subject against a disease, condition, infection, or virus thereof, by administering an effective amount of a nucleoside, short oligonucleotide compound or an analog thereof, or a pharmaceutically acceptable salt, racemate, enantiomer, diastereomer, geometric isomer, or tautomer thereof. In addition, the invention provides methods for treating or preventing a viral infection, bacterial infection, parasitic infection, or fungal infection in a subject (such as, a human). The compounds of the invention include, for example, di-, and trinucleotide compounds as provided herein. The compounds of the invention are useful for different therapeutic applications including, such as, prophylactics and therapeutics. The invention also provides design and synthesis of a compound that is useful for various therapeutic applications as mentioned herein. | 2015-12-31 |
20150374817 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF BURNOUT SYNDROME - The present invention is directed to a pharmaceutical composition or a kit-of-parts and its use in the treatment of burnout syndrome and longevity therapy. | 2015-12-31 |
20150374818 | INORGANIC NANOPARTICLES COMPOSITIONS IN COMBINATION WITH IONIZING RADIATIONS FOR TREATING CANCER - The present application relates to activable inorganic nanoparticles which can be used in the health sector, in particular in human health, to disturb, alter or destroy target cancerous cells, tissues or organs. It more particularly relates to nanoparticles which can generate a surprisingly efficient therapeutic effect, when concentrated inside the tumor and exposed to ionizing radiations. The invention also relates to pharmaceutical compositions comprising a population of nanoparticles as defined previously, as well as to their uses. | 2015-12-31 |
20150374819 | PHTHALOCYANINE PROBES AND USES THEREOF - The present invention relates to compositions and methods for destroying target cells in a patient using photodynamic therapy. In particular, the present invention provides a photosensitizing agent based on a small molecular weight (<50 kDa) protein or peptide or a small molecule that is conjugated to a phthalocyanine dye, such as IRDye® 700DX. | 2015-12-31 |
20150374820 | DIFLUPREDNATE EMULSION COMPOSITION CONTAINING ZINC - The present invention relates to an emulsion composition containing difluprednate and zinc. The present invention also relates to a method of stabilizing an emulsion composition containing difluprednate, the method includes preparing an emulsion composition comprising difluprednate and zinc. According to the present invention, a difluprednate-containing emulsion composition having excellent preservative efficacy and excellent stability (photostability and heat stability) can be provided. | 2015-12-31 |
20150374821 | METHODS AND COMPOSITIONS FOR SELF-REGULATED RELEASE OF ACTIVE PHARMACEUTICAL INGREDIENT - An abuse deterrent pharmaceutical composition including a pharmaceutically active ingredient; an acid soluble ingredient; and a buffering ingredient; wherein the acid soluble ingredient and the buffering ingredient retard release of the active pharmaceutical ingredient when the composition is ingested in excess of an intended dosage. | 2015-12-31 |
20150374822 | METHODS AND APPARATUS FOR THE ENHANCED DELIVERY OF THE PHYSIOLOGIC AGENTS TO TISSUE SURFACES - Apparatus and methods deliver physiologically active agents in the presence of adjuvant gases. The adjuvant gases can enhance the effectiveness of the drug, lower the dosage of drug or concentration of drug necessary to achieve a therapeutic result, or both. Exemplary adjuvant gases include carbon dioxide, nitric oxide, nitrous oxide, and dilute acid gases. | 2015-12-31 |
20150374823 | POLYALKOXYLATED ALCOHOLS AS EXCIPIENTS FOR PHARMACEUTICAL COMPOSITIONS - The present invention relates to the use of polyalkoxylated alcohols of the formula R—O-(AO)—H, wherein R is a substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl, aralkyl or heterocyclic group having 7 to 25 carbon atoms, (AO) is a polyoxyalkylene moiety of the composition (BO)m(EO)n(DO)r with random or blockwise arrangement of the constituting oxyalkylene units, wherein m, n and r represent the average number of oxybutylene (BO) units, oxyethylene (EO) units and oxyalkylene units derived from at least one epoxide selected from styrene oxide and alkylene oxides having from 5 to 10 carbon atoms (DO) per molecule of the polyalkoxylated alcohol, respectively, m being a number greater than or equal to 1, n being a number greater than or equal to 1 and r being a number in the range from 0 to 50 under the proviso that (m+n+r) is less than or equal to 200 and the ratio n/(m+r) is in the range of 1 to 20, as excipients in pharmaceutical compositions. Said polyalkoxylated alcohols enable very effective solubilisation of poorly soluble active pharmaceutical ingredients in aqueous media. Solid or semi-solid pharmaceutical compositions comprising one or more such polyalkoxylated alcohol combined with at least one active pharmaceutical ingredient are further long term stable under typical storage conditions and can be readily provided in various dosage forms such as tablets and filled capsules. | 2015-12-31 |
20150374824 | STABLE NOCATHIACIN LYOPHILIZED INJECTION AGENT - A stable and lyophilized pharmaceutical agent containing nocathiacin, which is prepared by lyophilizing a liquid formulation of nocathiacin, a stabilizer, an excipient, a pH regulator and injectable water, wherein the stabilizer is selected from polyethylene glycol, polysorbate or a mixture thereof, and the pH value of the liquid formulation is 1.0-6.0 is provided. | 2015-12-31 |
20150374825 | Stable Glucagon Formulations - Stabilized formulations containing a peptide, such as a glucagon, are described herein. The formulations are in the form of a solution or suspension, which exhibit ttle or no chemical degradation and/or aggregation of the peptide over an extended period of time. In some embodiments, the formulations are in the form of a solution containing the peptide, a solvent such as glycerin, and one or more thermal stabilizers. In other embodiments, the formulation is in the form of a suspension containing nano- and/or microparticles containing the peptide suspended in a non- aqueous, non-solvent. The nano- and/or microparticles can be prepared by micronizing the peptide with one or more humectants, such as salts, sugars, water-soluble polymers, and combinations thereof which increase the rate of dissolution of the peptide upon administration. | 2015-12-31 |
20150374826 | PHARMACEUTICAL COMPOSITIONS AND DOSAGE FORMS FOR ADMINISTRATION OF HYDROPHOBIC DRUGS - Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs are provided. The pharmaceutical compositions include a therapeutically effective amount of a hydrophobic drug, preferably a steroid; a solubilizer, and a surfactant. The synergistic effect between the hydrophobic drug and the solubilizer results in a pharmaceutical formulation with improved dispersion of both the active agent and the solubilizer. As a result of the improved dispersion, the pharmaceutical composition has improved bioavailability upon administration. Methods of improving the bioavailability of hydrophobic drugs administered to a patient are also provided. | 2015-12-31 |
20150374827 | SOLID DISPERSIONS OF LOW-WATER SOLUBILITY ACTIVES - Disclosed are compositions including a solid dispersion comprising a dispersion polymer, a basic low-water solubility active, and an anionic counterion, as well as methods of making and using the compositions. | 2015-12-31 |
20150374828 | GLUCOSE-SENSITIVE NANOPARTICLE FOR CANCER DIAGNOSIS AND THERAPY - Disclosed are glucose-sensitive nanoparticles which includes a phenylboronic acid derivative and a biocompatible polymer, and is prepared as an amphiphilic conjugate having chemical binding between the phenylboronic acid derivative and the biocompatible polymer. The use of the composition can effectively collect glucose in the cancer tissue, thereby simultaneously performing diagnosis and therapy of cancer. | 2015-12-31 |
20150374829 | POLYMER SUPPORT FOR THE DISTRIBUTION OF A NATURALLY CRYSTALLINE SUBSTANCE AND PRODUCTION METHOD - The invention relates to the implementation of a method for loading, without a vehicle, a naturally crystalline substance solubilised by a solvent mixture in a lipophilic medium in a mixture of granulated polymers, for forming, without a plasticiser, a polymer support for the long-term controlled distribution of the naturally crystalline substance in the stable solubilised state, without permanent crystallisation on the surface of said support. Said substance according to the invention can be insecticides and pesticides of the group of pyrethroids (e.g. deltamethrin), formamidines (e.g. amitraz) and carbamates (e.g. propoxur), or the mixture thereof, or cosmetics of the group of alkaloids (e.g. caffeine), or medicaments (e.g. ibuprofen). The permanent non-crystallisation state on the surface of the polymer support is only ensured when said substance is solubilised in the solvent mixture consisting of an oxygenated solvent of dibasic esters of methylenic fatty acids and an oxygenated methylenic cosolvent in an active lipophilic solution incorporated into a polymer mixture consisting of a polyether block amide (PEBA) and a thermoplastic polyurethane elastomer (TPU). Said support can be shaped as a collar, as an ear tag for animals, a band, a patch, a tag, a polymer block or any other device for the distribution of the active substances. It is shaped by any one of the plastic processing techniques known by a person skilled in the art. It is advantageous in that it is loaded with a quantity of active substance of between 30% and 50% less than the previous devices for at least the same active efficiency. | 2015-12-31 |
20150374830 | MEDICAL DEVICES AND METHODS COMPRISING AN ADHESIVE SHEET CONTAINING A DRUG DEPOT - Improved medical devices and methods are provided that are implantable at or near a target tissue site beneath the skin of a patient, the medical device comprises an adhesive sheet having a region configured to receive a drug depot, the drug depot disposed within the region of the adhesive sheet and the drug depot having at least one surface configured to release a therapeutically effective amount of the drug over a period of at least one day, wherein the adhesive sheet limits movement of the medical device at or near the target tissue site. In some embodiments, the medical device provided can include an effective amount of at least one analgesic and/or at least one anti-inflammatory agent at or near a target site, and can reduce, prevent or treat inflammation and/or pain, particularly postoperative pain or orthopedic degenerative pathology pain. | 2015-12-31 |
20150374831 | NOVEL ESTERIFIED CELLULOSE ETHERS OF LOW VISCOSITY - Esterified cellulose ethers which comprise (i) aliphatic monovalent acyl groups or (ii) groups of the formula —C(O)—R—COOA, wherein R is a divalent aliphatic or aromatic hydrocarbon group and A is hydrogen or a cation, or (iii) a combination of aliphatic monovalent acyl groups and groups of the formula —C(O)—R—COOA, which have a viscosity of up to 2.33 mPa·s, measured as a 2.0 wt % solution of the esterified cellulose ether in 0.43 wt % aqueous NaOH at 20° C., and which have a viscosity of up to 13 mPao·s, measured as a 10 wt % solution of the esterified cellulose ether in acetone at 20° C. are useful for preparing solid dispersions comprising drugs. | 2015-12-31 |
20150374832 | EPINEPHRINE FORMULATIONS FOR MEDICINAL PRODUCTS - The invention relates to compositions of epinephrine formulation in an aqueous solution that enhances the chemical stability of epinephrine and consequently extends the product shelf life. The formulation comprises epinephrine or a salt thereof, a tonicity modifier, and a complexing agent, in an aqueous solution adjusted to a pH of about 2-7. A process for manufacturing and methods of using the formulation for the medicinal products are also provided. | 2015-12-31 |
20150374833 | POLYPEPTIDE HYDROGEL AND METHOD FOR PRODUCING SAME - A polypeptide hydrogel of the present invention is a hydrogel of a polypeptide derived from spider silk proteins, and has a moisture content of 85.0 to 99.9 mass % based on 100 mass % of the polypeptide hydrogel. A method for producing the hydrogel includes: a solution production step in which a polypeptide derived from spider silk proteins is dissolved in at least one dissolving solvent selected from the group consisting of: (A) dimethyl sulfoxide; (B) dimethyl sulfoxide with an inorganic salt; and (C) N, N-dimethylformamide with an inorganic salt, so as to obtain a solution of the polypeptide; and a substitution step in which the solution produced in the solution production step is substituted with a water-soluble solvent. Thus, the present invention provides a polypeptide hydrogel having excellent water retentivity and a polypeptide hydrogel suitable for application to a living body. | 2015-12-31 |
20150374834 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS TO SOLID TUMORS - The present invention provides novel, serum-stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides serum-stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (e.g., one or more interfering RNA molecules), methods of making the SNALP, and methods of delivering and/or administering the SNALP (e.g., for the treatment of cancer). In particular embodiments, the present invention provides tumor-directed lipid particles that preferentially target solid tumors. The tumor-directed formulations of the present invention are capable of preferentially delivering a payload such as a nucleic acid to cells of solid tumors compared to non-cancerous cells. | 2015-12-31 |
20150374835 | LIQUID TOPICAL PHARMACEUTICAL NANO-EMULSION FORMULATIONS - Aspects of the present invention are directed to compositions that are useful for delivery of an active ingredient to a subject. Some embodiments are formulated with an active ingredient, including, for example, a non-steroidal anti-inflammatory drug (NSAID), such as aspirin, ibuprofen, ketoprofen, or naproxen, acetaminophen, or a polypeptide or protein, such as insulin, wherein the active ingredient is stabilized and greater than 90% of the particles of the active ingredient have a particle size that is less than or equal to or any number in between 100, 90, 80, 70, 60, 50, 40, 30, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, or 4 nanometers, or smaller, as determined by Dynamic Light Scattering (DLS), using a volume-weighted particle size distribution calculation method. | 2015-12-31 |
20150374837 | ANTIBACTERIAL AGENT FOR TREATING INFECTIOUS DISEASES OF BACTERIAL ORIGIN - The invention relates to medicine, namely to the antimicrobial agent for the treatment of infectious bacterial diseases including hospital infections and drug-resistant TB which represents the ion nanostructured complex (INSC) synthesized from carbohydrates proteins and/or polypeptides (albumins, interleukins, interferons, signaling proteins, etc), which are to enhance the antimicrobial activity in vivo, by activating immune cells that contain at least one terminal amino acid such as Phe, Ala, Val, Ala, Leu, Ile, and others with electron-donor functional groups, iodine and halides of the alkali and alkaline earth elements in the fourth stage at a certain ionic strength; an antibacterial agent increases: the susceptibility of bacteria, including antibiotic-resistant, to antibiotics; activity of monocytes and macrophages; efficiency of antibiotic treatment of hospital infections and drug-resistant TB; it also has antiviral activity, stimulates hematopoietic function of bone marrow; has an antitumor effect and radioprotective properties; in acceptable concentrations of components can be used as non-pharmaceutical agent (BAFS or parapharmaceutical); is presented in the pharmacological form suitable for parenteral, oral, external, or other application. INSC has the formula [{(Ln(MeI3)+)y[Me(Lm)I]+x}(Cl—)y+x+k] with M=30-300 kDa. | 2015-12-31 |
20150374838 | A POLYMERIC SYSTEM FOR RELEASE OF AN ACTIVE AGENT - The present disclosure relates to a polymeric system for release of an active agent, comprising a first polymeric phase containing the active agent, the first polymeric phase forming discrete regions of a set size range and being dispersed within a second polymeric phase comprising a cross-linked polymer-phenol conjugate for release of the active agent therein. The present disclosure further provides an injectable hydrogel comprising the disclosed polymeric system, a carrier for delivering a biologically active substance or a drug comprising the injectable hydrogel, and a method for producing the disclosed polymeric system. | 2015-12-31 |
20150374839 | NOVEL FATTY ACID-SALICYLATE CONJUGATES WITH ENHANCED THERAPEUTIC PROPERTIES - The invention provides compositions and methods for treating or preventing cancer with an inventive composition. The invention relates to the fields of biomedicine, pharmacology, and molecular biology. | 2015-12-31 |
20150374840 | MODIFIED PEPTIDES AND PROTEINS - Provided are compounds and methods of making compounds containing two or three groups derived from a peptide, such as enfuvirtide or exenatide, covalently bound to a linker. The compounds may contain polyethylene glycol groups to enhance solubility and pharmacokinetic properties. The compounds are useful for the treatment of diseases or conditions subject to treatment with the parent peptide, such as HIV and AIDS in the case of enfuvirtide, or diabetes in the case of exenatide. | 2015-12-31 |
20150374841 | Oligonucleotide Conjugates - Oligonucleotide conjugates, where an oligonucleotide is covalently attached to an aromatic system, are provided. In particular embodiments the oligonucleotide is complementary to the RNA component of human telomerase and is covalently attached to a nucleobase via an optional linker. The conjugates inhibit telomerase enzyme activity. | 2015-12-31 |
20150374842 | PROCESS FOR FORMULATING AN ANIONIC AGENT - Formulations comprising anionic agents such as nucleic acids within a lipid-containing particle methods of formulating a lipid-containing particle comprising an anionic agent such as a nucleic acid, methods for preparing a lipid-containing particle comprising an anionic agent such as a nucleic acid, methods for therapeutic delivery of an anionic agent to a patient in need thereof, where the anionic agent is formulated in a lipid-containing particle as described herein. | 2015-12-31 |
20150374843 | MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS - The invention provides compositions and methods for therapeutic and diagnostic applications. | 2015-12-31 |
20150374844 | NOVEL PH -SWITCHABLE PEPTIDES FOR MEMBRANE INSERTION AND PORE FORMATION - Disclosed herein is a pH-switchable pore formation (PSPF) peptide comprising one or more amino acids in peptide sequence whose charge state and hydrophobicity are pH-dependent, wherein the peptide can bind to a biological membrane upon contact and form pores on the membrane at pH of less than about 7, and wherein the peptide forms substantially no pores on the biological membrane at pH of greater than about 7. Also disclosed is a modular composition comprising: a) one or more PSPF peptides, which may be the same or different; b) a single stranded or double stranded oligonucleotide; and c) one or more linkers, which may be the same or different. | 2015-12-31 |
20150374845 | COMPOUNDS THAT BIND DYSTROGLYCAN AND USES THEREOF - Disclosed herein are methods and compositions involved in identifying cells that lack apico-basal polarity as well as methods and compositions involved in selectively delivering payload molecules to cells that lack apico-basal polarity, and methods of selecting test compounds that restore apico-basal polarity. | 2015-12-31 |
20150374846 | Methods and Compositions for Generating Bioactive Assemblies of Increased Complexity and Uses - The present invention concerns methods and compositions for making and using bioactive assemblies of defined compositions, which may have multiple functionalities and/or binding specificities. In particular embodiments, the bioactive assembly is formed using dock-and-lock (DNL) methodology, which takes advantage of the specific binding interaction between dimerization and docking domains (DDD) and anchoring domains (AD) to form the assembly. In various embodiments, one or more effectors may be attached to a DDD or AD sequence. Complementary AD or DDD sequences may be attached to an adaptor module that forms the core of the bioactive assembly, allowing formation of the assembly through the specific DDD/AD binding interactions. Such assemblies may be attached to a wide variety of effector moieties for treatment, detection and/or diagnosis of a disease, pathogen infection or other medical or veterinary condition. | 2015-12-31 |
20150374847 | ANTI-PMEL17 ANTIBODIES AND IMMUNOCONJUGATES - The invention provides anti-PMEL17 antibodies and immunoconjugates and methods of using the same. | 2015-12-31 |
20150374848 | Methods for the Treatment of Head and Neck Squamous Cell Carcinoma - This invention relates to the staging, diagnosis, and treatment of cancerous diseases, particularly to the use of monoclonal antibodies, antigen binding fragments thereof, and/or cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more CDMAB, chemotherapeutic agents, and conjugates thereof, as a means for initiating a cytotoxic response to human head and neck squamous cell carcinomas. The invention further relates to binding assays, which utilize the monoclonal antibodies, antigen binding fragments thereof, and/or CDMAB of the instant invention. The cancerous disease modifying antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells. In particular aspects, the CDMAB used in the methods of the invention is an anti-CD44 antibody, which may be the antibody produced by the hybridoma deposited with the ATCC having accession number PTA-4621 and/or a chimeric or humanized version thereof. | 2015-12-31 |
20150374849 | NANOPARTICLES FOR DRUG DELIVERY - The invention provides nanoparticles, methods for making nanoparticles, and methods for using nanoparticles. An important attribute of a drug delivery system is its ability to allow for spatial and temporal regulated drug release, thereby minimizing side effects and improving therapeutic efficacy of conventional pharmaceuticals. Iron oxide nanoparticles (NPs), specifically Fe304 nanoparticles, possess many appropriate qualities that make them a viable choice for drug delivery. | 2015-12-31 |
20150374850 | COMPOSITION FOR GENE DELIVERY COMPRISING CHITOSAN AND LIQUID CRYSTAL FORMATION MATERIAL - Disclosed herein is a composition for gene delivery which forms into liquid crystals in an aqueous fluid including chitosan and a liquid crystal formation material. The composition of the present invention including chitosan and a liquid crystal formation material improves the relatively low binding strength between chitosan and a gene, and also considerably increases the stability of a chitosan nanocomposite in blood serum, thereby performing highly efficient gene delivery and providing excellent stability, thus being useful as a gene therapeutic agent. | 2015-12-31 |
20150374851 | AAV VECTORS EXPRESSING SEC10 FOR TREATING KIDNEY DAMAGE - A method for enhancing repair of damaged mammalian tubular epithelial cells involves delivering to the tubular epithelial cells of a subject in need thereof a composition comprising an adeno-associated virus (AAV) comprising an AAV capsid having an amino acid sequence of a selected AAV serotype, and a minigene having AAV inverted terminal repeats and a Sec10 gene operatively linked to regulatory sequences that direct expression of Sec10 in the epithelial cells. In one embodiment, delivery is accomplished by retrograde intrauretal injection. In an embodiment the AAV vector includes a capsid of AAV serotype 2/8. Therapeutic compositions containing such AAV are provided. | 2015-12-31 |
20150374852 | Use of IGF-1 as a Reagent for Early Diagnosis and/or Prognosis of Alzheimer Disease - The invention relates to the use of the insulin-like growth factor (IGF-1) as a reagent for the early diagnosis and/or prognosis of Alzheimer disease, to a kit comprising IGF-1 and a sedative, and to the use thereof in the early diagnosis and/or prognosis of Alzheimer disease. | 2015-12-31 |
20150374853 | BRAIN TUMOR TARGETING PEPTIDES AND METHODS - A method of diagnosing and treating a human glioblastoma multiforme (GBM) brain tumor in a subject is disclosed. The method includes administering to the subject, an effective amount of composition having a peptide 12-20 amino acid residues in length and selected for its ability to bind preferentially to a subtype of human GBM cells identified as brain tumor initiating cells (BTICs) or highly invasive glioma cells (HIGCs). | 2015-12-31 |
20150374854 | HYPERPOLARIZED ESTERS AS METABOLIC MARKERS IN MR - The invention relates to a method of Magnetic Resonance (MR) detection, in particular | 2015-12-31 |
20150374855 | ORAL CONTRAST MEDIUM FOR THE DIAGNOSTIC INVESTIGATION OF THE GASTROINTESTINAL TRACT BY MEANS OF MPI - The invention relates to a pharmaceutically acceptable colloidal suspension, which comprises a microcapsule, which is enclosed by a container (“double container”), wherein the microcapsules comprise magnetic particles in a colloidal solution. The invention further relates to the use of said pharmaceutically acceptable colloidal suspension as an oral contrast medium for the diagnostic investigation of the gastrointestinal tract and the use of the contrast medium to diagnose proliferative diseases, inflammatory and autoimmune diseases, infectious diseases and hormonal and hereditary diseases in the gastrointestinal tract. | 2015-12-31 |
20150374856 | NEAR-INFRARED DYE-CONJUGATED HYALURONIC ACID DERIVATIVE AND CONTRAST AGENT FOR OPTICAL IMAGING INCLUDING THEM - Provided is a compound having a high ICG content that has high accumulation property in a tumor and has a large intensity of a photoacoustic signal emitted from the tumor even when a time period elapses after administration. Specifically, provided is a hyaluronic acid derivative to which polyethylene glycol and an ICG derivative are conjugated. | 2015-12-31 |
20150374857 | Method for predicting autism spectrum disorders by cannabinoid and cannabinoid receptor expression - The inventive method relates to a method for the determination of susceptibility or diagnosis of autism or autism spectrum disorders. Diagnosis or determination of susceptibility determinations are predicated on quantitative analysis of endocannibinoid levels or endocannibinoid receptor expression. | 2015-12-31 |
20150374858 | CONJUGATES DERIVED FROM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND METHODS OF USE THEREOF IN IMAGING - Conjugates derived from non-steroidal anti-inflammatory drugs (NSAIDs) and methods of use thereof are disclosed, useful for, inter alia, identifying and localizing the site of pathology and/or inflammation responsible for the sensation of pain in a patient; for identifying the sites of primary, secondary, benign, or malignant tumors; and for diagnosing infection or confirming or ruling out suspected infection. The NSAID-based conjugates contain an imaging moiety. The conjugates concentrate at sites of increased cyclooxygenase expression, thus revealing the sites of increased prostaglandin production, which is correlated with pain and inflammation, and correlated with tumor presence and/or location. Identifying areas of increased COX expressing can also aid in screening for infections. | 2015-12-31 |
20150374859 | Imaging compounds for tracking histone deacetylase inhibitor and synthesis method thereof - A synthesis method of labeling histone deacetylase inhibitor (HDAC inhibitors) SC027 with Gallium-67 or Gallium-68 radionuclide, wherein a labeled precursor DOTA-SC027 which comprises DOTA-NHS-ester (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-N-hydroxysuccinimide-ester) and HDACi-SC027 is prepared for the synthesis to label HDACi-SC027 with Gallium-67 or Gallium-68 radionuclide for producing imaging tracers for tracking the HDACi. | 2015-12-31 |
20150374860 | TREATMENT OF METASTATIC TUMORS - The present invention is directed to methods and methods for the treatment, inhibition and/or reduction, and detection of metastatic tumors. In some embodiments, the inventive methods include systemic (e.g., intravenous) administration of a chlorotoxin agent that may or may not be labeled. In some embodiments, the inventive methods allow treatment, inhibition and/or reduction, and detection of metastases in the brain. In some embodiments, neovascularization is inhibited and/or newly formed vessels are caused to regress. | 2015-12-31 |
20150374861 | KIT FOR TUMOR IMAGING - This invention relates to kits for tumor imaging and methods for preparing the kits using a composition having the structure— His-Ser-Asp-Gly-Ile-Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Ala-Ala-Val-Leu-yAba-Lys (R) (SEQ ID NO:1), wherein the y-amino group of the lysine residue is coupled to a chelator disclosed in this application. | 2015-12-31 |
20150374862 | COMPOSITIONS AND METHODS FOR DETECTING PLECTIN-1 AS A BIOMARKER FOR CANCER - The present invention provides compositions and methods useful for diagnostic and imaging techniques for detecting and localizing the biomarker Plectin-1. The present invention provides multimeric peptide ligand complexes for targeting Plectin-1, such as the multimeric peptide ligand complex having the formula (βAKTLLPTPGGS(PEG5000)) | 2015-12-31 |
20150374863 | APPARATUS AND METHOD FOR THE PREPARATION AND STERILIZATION OF VISCOUS PRODUCTS CONTAINING TEMPERATURE SENSITIVE COMPOUNDS - An apparatus for the preparation and sterilization of a viscous fluid containing a temperature sensitive compound diluted into a viscous matrix, characterized in that it includes: a heat treatment unit, fed with the viscous matrix, wherein the viscous matrix is sterilized, a mixing unit, fed with the sterilized viscous matrix and the sterile temperature sensitive compound, wherein the temperature sensitive compound is incorporated into the sterilized viscous matrix to form the viscous fluid. | 2015-12-31 |
20150374864 | STERILIZING DEVICE AND STERILIZATION METHOD HAVING ENERGY RECOVERY - The present invention relates to a sterilising device ( | 2015-12-31 |
20150374865 | ATMOSPHERIC MICROWAVE STERILIZERS AND METHODS - An apparatus for sterilizing instruments at atmospheric pressure is provided. The apparatus includes a receiver, a sterilant reservoir, a rinsant reservoir, a waste reservoir, a microwave source, and a controller. The receiver receives the instruments to be sterilized and is made of a non-microwave absorptive material. The sterilant reservoir contains a sterilant fluid that is absorptive of microwave energy and has a boiling point greater than 100° Celsius. The rinsant reservoir contains a chemical rinsant fluid that is capable of solvating or displacing the sterilant fluid and does not support microbial viability or growth. The microwave source is positioned with respect to receiver so as to emit microwave energy into the receiver. The reservoirs are each in selective fluid communication with the receiver and the controller selectively moves the sterilant fluid or the chemical rinsant fluid from the reservoirs to the receiver and from the receiver to the waste reservoir. | 2015-12-31 |
20150374866 | AQUEOUS CLEANSER FOR DENTAL APPLIANCES - An aqueous composition is described herein that is safe, convenient, and effective for cleansing dental appliances. The primary cleansing agent in this composition is a surfactant, which allows for fast and effective cleaning without damaging or discoloring the plastic of the dental appliance. The stable aqueous composition does not require dissolving in a reservoir and may be applied directly to the dental appliance. The aqueous composition is safe for natural teeth and therefore easy to incorporate into a regular oral hygiene routine. | 2015-12-31 |
20150374867 | Sanitizing Device - A sanitizing device used to sanitize a bulb syringe. The device preferably includes a base, a bulb receiver, and a sanitization system. The sanitization system produces a sanitizing gas that is propelled into and possibly around a bulb syringe in order to sanitize the surfaces of the syringe. The sanitization system preferably includes an ionization module, a fan, electrodes, and a power supply. Preferably, the sanitization system is housed in a conical housing which includes a central nozzle and an array of openings centered around the nozzle exit. The sanitization device preferably includes an automatic switch that is activated by the presence of a bulb syringe or upon placing a cover over the device. | 2015-12-31 |
20150374868 | STERILIZATION CONTAINER CAPABLE OF PROVIDING AN INDICATION REGARDING WHETHER OR NOT SURGICAL INSTRUMENTS STERILIZED IN THE CONTAINER WERE PROPERLY STERILIZED - A sterilization container for sterilizing at least one surgical instrument. The container includes at least one sensor for measuring an environmental characteristic of the container during the sterilization of the instrument. The measure of the environmental characteristic is supplied to a processor. The processor compares the measurement of the container environment to a validated measurement for the sterilization process. If the measured environmental characteristic is at least equal to the validated sterilization process measurement, the processor presents an indication that the surgical instruments was properly sterilized. | 2015-12-31 |
20150374869 | Methods, Compositions And Articles For Olfactory-Active Substances - The present invention is directed to methods, compositions and articles comprising olfactory-active compositions. An article of the present invention comprises a structural component and an olfactory-active composition. The article may control the release, release rate or absorption of the olfactory-active composition. The article may be of various shapes and sizes. A method of use of an article comprises providing fragrance to an environment. | 2015-12-31 |
20150374870 | MOBILE POWER PACK WITH FRAGRANCE FEATURE - The present invention provides a mobile power pack with fragrance feature is disclosed. An outer surface of the housing is formed with an accommodating space, and a power module is installed in the housing. A heating element is disposed in the housing and corresponding to the accommodating space, and the heating element is electrically connected with the power module. A fragrant shim is disposed in the accommodating space, and the fragrant shim is heated by the heating element for producing aromas. | 2015-12-31 |
20150374871 | DEVICE AND METHOD FOR DELIVERING VOLATILE SUBSTANCES - The present invention provides a device for delivering volatile substances, comprising: (i) a vapor permeable outer enclosure, said outer enclosure preferably being formed by a first laminate comprising a mesh material layer and a vapor permeable material layer laminated onto the mesh material layer; and (ii) a vapor impermeable inner enclosure placed inside the outer enclosure and defining an interior space for accommodating the volatile substances, said inner enclosure being formed by a second laminate comprising a metal foil layer and a rupturable material layer laminated onto the metal foil layer, wherein at least one die cut line to define a preformed hole is formed through the rupturable material layer. The invention also provides a method for delivering volatile substances. | 2015-12-31 |
20150374872 | ACTIVE SUBSTANCE DISPENSING DEVICE - The dispensing device comprising an active substance dispensing element ( | 2015-12-31 |
20150374873 | VENT STICK AIR FRESHENER WITH DUAL ACTION BODIES AND AIR FLOW TUNNEL - A vent stick air freshener has a pair of vent rods extending rearwardly from an annular head with a hollow therein, an open front end and an open rear end defining an air tunnel. At least one body is carried by at least one of the pair of vent rods. An insert is at least partially received in the hollow of the annular head. A space is defined between the insert and the annular head. The at least one body or the insert or both has a desired scent material interspersed therein and diffusible out over time. | 2015-12-31 |
20150374874 | Adaptable Diffuser - A system and for diffusing. The system includes a diffuser body and two angled sides. The diffuser also includes a removable cover which is coupled to the diffuser body via a coupling device. Further, a shield is coupled to the diffuser body. The diffuser houses a container which is at least partially filled with a fragrance which is to be emitted by the diffuser. The removable cover hides the container from view. The diffuser is shaped to allow the diffuser to be placed in a corner. Further, because the cover can be removed, the cover can be customized and adjusted for a more aesthetically pleasing diffuser. | 2015-12-31 |
20150374875 | ABSORBENT ARTICLE COMPRISING A COOLING SYSTEM - An absorbent article comprising a cooling system, where the cooling system comprises one or more cooling agents which are selected oxalic acid derivatives. The cooling system is stable, does not require special packaging and still provide a cooling sensation even after storage of the products. | 2015-12-31 |
20150374876 | HIGH INTERNAL PHASE EMULSION FOAM ASSOCIATED WITH POLYURETHANE FOAM - An absorbent structure having HIPE foam that comprises polyurethane foam. | 2015-12-31 |
20150374877 | Chitosan Foam Medical Devices and Methods - The invention provides a solid foam wound dressing useful for hemorrhage control and wound repair, as well as methods for making such a wound dressing. | 2015-12-31 |
20150374878 | ANGIOGENIC DEVICES FOR WOUND CARE - Devices, such as dressing and implants, for treatment of chronic wounds comprising controlled delivery systems for butyric acid or salts, polymers, or derivatives thereof are provided. These devices are particularly useful when it is desirable to promote angiogenesis in a chronic wound. In the preferred embodiment, the implants are resorbable, provide a temporary scaffold for the in-growth of cells, tissues, and blood vessels to help regenerate the extracellular matrix, and deliver butyric acid to the chronic wound. The dressings and implants may also contain one or more antibiotics to treat or prevent infection in the wound, and/or inhibitors of proteases to modulate protease activity in the wound. | 2015-12-31 |
20150374879 | Vertebral Body Augmentation Systems Comprising Microbubbles - Adding gas-filled microbubbles to both the saline solution of either a kyphoplasty balloon or a vertebroplasty cement allows the clinician to assess via ultrasound both the location and expansion of the balloon and the location of the cement during vertebral body augmentation procedures without the use of fluoroscopy. | 2015-12-31 |
20150374880 | Solid Substrates for Mitigating or Preventing Cell and Tissue Adhesion and Vascularization - This invention provides solid substrates for mitigating or preventing cell or tissue adherence and/or vascularization, which solid substrate comprises a marine organism skeletal derivative and is characterized by a specific fluid uptake capacity value of less than 40%, which specific fluid uptake capacity value is determined by establishing a spontaneous fluid uptake value divided by a total fluid uptake value and processes for selection of an optimized marine organism skeletal derivative-based solid substrate for mitigating or preventing cell or tissue adherence and/or vascularization and applications of the same. This invention also provides solid substrates for mitigating or preventing cell or tissue adherence and/or vascularization, which solid substrate is characterized by having a contact angle value of more than 60 degrees, when in contact with a fluid. This invention also provides solid substrates for mitigating or preventing cell or tissue adherence and/or vascularization, which solid substrate is characterized by a minimal surface roughness (Ra) or substantial surface smoothness, as measured by scanning electron microscopy or atomic force microscopy. The invention also provides for processes for selection of an optimized coral-based solid substrate for mitigating or preventing cell or tissue adherence and/or vascularization and applications of the same. | 2015-12-31 |
20150374881 | HUMAN CORNEAL ENDOTHELIAL CELL SHEET - The present invention provides a human corneal endothelial cell sheet having a curvature fitting a human corneal endothelial surface, particularly, the human corneal endothelial cell sheet supported by a cell support having a curvature fitting a human corneal endothelial surface, and a production method of a human corneal endothelial cell sheet having a curvature fitting a human corneal endothelial surface, which includes the following steps:
| 2015-12-31 |
20150374882 | Porous material - Porous material made with metal or metal alloy, which may be a coating, can be made from a first intermediate and then a second intermediate. For instance, the first intermediate may be provided by providing the metal or metal alloy, and a pore-holding substance; and combining the metal or metal alloy, and the pore-holding substance. The second intermediate can be provided, for instance, by forming from the first intermediate, a matrix of metal or metal alloy, in which is dispersed the pore-holding substance, for example, with thermal spraying. The porous material can be made by contacting the second intermediate with a pore-forming substance under conditions such that pore-holding substance in the matrix contacted with the pore-forming substance is reduced in size or removed to leave pores in remaining metal or metal alloy to provide a constituent of a metal or metal alloy with pores. | 2015-12-31 |
20150374883 | Bone Graft Substitute Containing a Temporary Contrast Agent and a Method of Generating Such and A Method of Use Thereof - A bone graft substitute for use in orthopedic bone grafting procedures comprising a radiolucent bone graft substitute combined with a temporary radiopaque agent. Methods of making and using the composition are also disclosed. Bone graft substitutes have become an effective means of regenerating bone in orthopedic procedures where bone loss results from surgically created defects or traumatic injury to the bone. Bone graft substitutes include mineral-based materials such as hydroxyapatite, calcium phosphates, and calcium phosphosilicates as well as allograft-derived materials and xenograft-derived materials such as collagen-based matrices and demineralized bone matrices. | 2015-12-31 |
20150374884 | RADIOPAQUE POLYMERS FOR MEDICAL DEVICES - Radiopaque polymer compositions and methods for making the compositions are provided. These radiopaque polymer compositions include polymer compositions comprising a crosslinked polymer network, the network comprising a first repeating unit derived from a monofunctional monomer and a second repeating unit derived from a multifunctional non-iodinated monomer wherein neither of the two monomers is fluorinated. Devices formed from radiopaque polymer compositions are also provided. | 2015-12-31 |
20150374885 | Biodegradable Triblock Copolymers For Implantable Devices - The present invention is directed to polymeric materials made of biodegradable, bioabsorbable triblock copolymers and implantable devices (e.g., drug-delivery stents) containing such polymeric materials. The polymeric materials may also contain at least one therapeutic substance. The polymeric materials are formulated so as to improve the mechanical and adhesion properties, degradation, biocompatibility and drug permeability of such materials and, thus, implantable devices formed of such materials. | 2015-12-31 |
20150374886 | COATINGS WITH CRYSTALLIZED ACTIVE AGENT(S) AND METHODS - The present invention relates to coatings with crystallized active agent(s) and related methods. In an embodiment, the invention includes a method for coating a medical device including selecting a solvent and a polymer, selecting a concentration of an active agent of at least a certain amount of saturation, forming a coating composition having the selected concentration of the active agent, and applying the coating composition to the medical device. In an embodiment, the invention includes an elution control coating disposed on a medical device, the elution control coating including a polymer, and an active agent, wherein the active agent is at least about 80% crystallized within one week of being disposed on the medical device. In an embodiment, the invention includes a method for enhancing the formation of active agent crystals within a coating layer including forming a coating solution and adjusting the concentration of the active agent in the coating solution to reach some percentage of the active agent saturation point. In an embodiment, the invention includes a method of enhancing crystallization of an active agent, the method including forming a coating solution comprising a polymer, an active agent, and a solvent; applying the coating solution to a substrate; and increasing the rate of active agent nucleation within the coating. | 2015-12-31 |
20150374887 | DEVICES AND METHODS FOR THE PREVENTION AND TREATMENT OF NEUROMAS - In one aspect, nerve growth inhibition devices are described herein. In some embodiments, a nerve growth inhibition device described herein comprises a tube having a proximal end and a distal end. A matrix material is disposed in the tube, and the matrix material comprises one or more microchannels. The proximal end of the tube comprises an opening operable to receive nerve tissue, the distal end of the tube is sealed, and the microchannels of the matrix material extend from the proximal end of the tube toward the distal end of the tube. | 2015-12-31 |
20150374888 | TISSUE PARCELIZATION METHOD AND APPARATUS - Methods and systems for sizing fat parcels are provided. In particular, a parcelizer device that includes a container and a displacement insert or filter element is provided. Tissue containing fat parcels is passed through the parcelizer. The parcelizer can include multiple displacement inserts or filter elements. Alternatively or in addition, a plurality of displacement structures that each include one or more displacement inserts or filter elements can be provided. In general, the displacement inserts or filter elements are configured to progressively reduce the size of fat parcels included in tissue. | 2015-12-31 |
20150374889 | SURGICAL KITS FOR BODY CAVITY DRAINAGE AND RELATED METHODS - A surgical kit for draining a body cavity of a patient includes a sterile enclosure, a body cavity drainage device with a sterilized drainage tube having one or more lateral openings through a side wall thereof, and a sterilized body cavity drainage tube placement tool configured to be inserted through a lateral opening of the one or more lateral openings. The body cavity drainage device and the placement tool are contained within the sterile enclosure. Methods relate to providing surgical tools for draining a body cavity of a patient. | 2015-12-31 |
20150374890 | BODY CAVITY DRAINAGE DEVICES INCLUDING DRAINAGE TUBES HAVING INLINE PORTIONS AND RELATED METHODS - A body cavity drainage device includes a drainage tube with a distal end configured for insertion into the body cavity of a patient, a fluid outlet at a proximal end of the drainage tube; and an activation apparatus coupled to the drainage tube between the proximal end of the drainage tube and the distal end of the drainage tube. The activation apparatus may be configured to alter a position of the distal end of the drainage tube in response to an input at a control device of the activation apparatus, and a first portion of the drainage tube extending from the activation apparatus toward the distal end may be at least substantially coaxial with a second portion of the drainage tube extending from the activation apparatus toward the proximal end. Methods relate to forming a body cavity drainage devices. | 2015-12-31 |
20150374891 | PLACEMENT TOOLS FOR BODY CAVITY DRAINAGE DEVICES AND RELATED METHODS - A body cavity drainage device placement tool for placing a body cavity drainage tube at least partially within a body cavity of a patient. The body cavity drainage device includes a shaft, a handle attached to or integral with a proximal end of the shaft, and a distal end of the shaft sized and configured for insertion through a lateral opening of the body cavity drainage tube and at least partially through a central lumen of the body cavity drainage tube to proximate a distal end of the body cavity drainage tube. Methods relate to using a body cavity drainage device placement tool. | 2015-12-31 |
20150374892 | CABLE SYSTEM FOR IMPLANTABLE BLOOD PUMP WITH ACCIDENTAL DISCONNECTION PREVENTION - A blood pump system includes a pump that is to be implanted in a patient and a control unit disposed externally of the patient. A percutaneous cable section is configured to pass percutaneously through an incision in the patient and has first and second ends. The second end is connectable to the pump. An extension cable section has second ends, and the second end is connectable to the control unit. The first and of the cable sections removably mate together and include a push-pull electrical connector covered by a secondary threaded mechanical connector. | 2015-12-31 |
20150374893 | CONTROLLER AND POWER SOURCE FOR IMPLANTABLE BLOOD PUMP - Methods and apparatus for controlling the operation of, and providing power for and to, implantable ventricular assist devices which include a brushless DC motor-driven blood pump, are disclosed. In one embodiment, a control system for driving an implantable pump is provided. The digital processor is responsive to data associated with the operation of the pump received at the data transfer port, and from the program data stored in memory, (i) to determine therefrom, the identity of the pump, (ii) to determine therefrom, electrical characteristics and features of the identified pump, and (iii) to adaptively generate and apply to the data port, control signals for driving the identified pump. Latch mechanisms, an elongated flexible electrical cable with a strain relief segment, and a lower housing portion that is heavier than an upper housing portion, may also be provided with the control system. | 2015-12-31 |
20150374894 | MEDICAL APPLIANCE - This invention relates to a medical appliance, in particular an apparatus for the extracorporeal blood treatment, with a housing including a door and with a handle mechanism arranged at the door, by means of which the door can be locked with the housing via a locking mechanism, wherein a part of the locking mechanism is formed at the handle mechanism in its part protruding into the housing and wherein a form-fit unit is provided which includes at least one form-fit means and at least one form-fit means counterpart, wherein on locking and/or closing the door the at least one form-fit means at least partly engages in the at least one form-fit means counterpart. | 2015-12-31 |
20150374895 | WATER TREATMENT SYSTEMS, DEVICES, AND METHODS FOR FLUID PREPARATION - A water purification component, which may be integrated in a medicament production plant and/or a blood treatment system, removes chloramine and other chlorine compounds and deionizes water. The deionization is selected to be effective for providing product water whose resistivity is sufficiently high to allow chloramine to be detected in the product water if the chloramine removal filtration fails. This allows a chloramine removal filter to be changed based on a predicted exhaustion schedule with the safety of automatic chloramine breakthrough provided. | 2015-12-31 |
20150374896 | Needle dislodgement and blood leakage detection device - A needle dislodgement and blood leakage detection device includes a sensor assembly including a flexible sensor and an alarm device to which the sensor assembly is mounted. The flexible sensor includes two blood leakage detection electrodes that circumferentially surround a needle piercing site. The blood leakage detection electrodes are contactable by a needle in a manner of crossing therebetween to get shorted or are contactable with blood leaking out of the needle piercing site to get shorted. The alarm device is positionable on a body surface of a patient and is electrically connected to the blood leakage detection electrodes so as to issue an alarm message when the detection electrodes are shorted. The flexible sensor has a thin plate configuration that is flexible allows the flexible sensor to be flat attached to the patient body surface and deformable with the bending of a limb of the patient. | 2015-12-31 |
20150374897 | APPARATUS FOR BLOOD PURIFICATION BY EXTRACORPOREAL CIRCULATION - A device for purifying blood includes an extracorporeal blood circulation loop, flow rate control elements to manage the blood circulation in the extracorporeal blood circulation loop, blood purification elements configured on the extracorporeal blood circulation loop, citrate injection elements for injecting a solution including citrate into the extracorporeal blood circulation loop, and a control unit configured to control the citrate injection elements and the flow rate control elements. The control unit is further configured to require, at determined time intervals of a blood purification treatment used by the device, the entry of at least one representative value of the status of the device and/or of the patient. The control unit then verifies the adequacy of the representative value with pre-established rules stored in the control unit and controls the citrate injection elements and/or the flow rate control elements in accordance with the result of the verification and the pre-established rules. | 2015-12-31 |
20150374898 | BLOOD PURIFICATION COLUMN - A blood purification column includes an adsorbent and a casing whose two ends are open ends, wherein the adsorbent is housed inside the casing, and wherein one of two casing ends is a blood inflow-side end portion and another is a blood outflow-side end portion, and wherein a filter is disposed at the blood inflow-side end portion and/or the blood outflow-side end portion of the casing, and wherein the filter satisfies (1)-(3):
| 2015-12-31 |
20150374899 | BLOOD BAG SYSTEM AND BLOOD TREATMENT METHOD - A blood bag system includes: a first bag in which blood containing multiple components is stored; a second bag in which a relative medium-density component is stored; a third bag in which a relative low-density component is stored; a first tube through which the relative low-density component and the relative medium-density component are transported from the first bag to the second bag; and a second tube through which the relative low-density component is transported from the first bag to the third bag. A blood treatment method involves: centrifuging blood containing multiple components in a first bag, transporting a low-density component from the first bag to a third bag through a first tube and transporting a relative medium-density component from the first bag to the second bag through the first tube. | 2015-12-31 |
20150374900 | CENTRIFUGAL SEPARATION CONTAINER, CENTRIFUGAL SEPARATION DEVICE, AND CENTRIFUGAL SEPARATION METHOD USING SAID CONTAINER AND DEVICE - A storage portion forming a storage space | 2015-12-31 |